A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine

Noroviruses (NoV) are the leading cause of epidemic acute gastroenteritis in humans worldwide and a safe and effective vaccine is needed. Here, a phase I, double-blind, placebo-controlled clinical trial was performed in 60 healthy adults, 18 to 40 years old. Safety (primary objective) and immunogeni...

Full description

Bibliographic Details
Main Authors: Isabel Leroux-Roels, Cathy Maes, Jasper Joye, Bart Jacobs, Franziska Jarczowski, André Diessner, Yorick Janssens, Gwenn Waerlop, Kirsi Tamminen, Suvi Heinimäki, Vesna Blazevic, Geert Leroux-Roels, Victor Klimyuk, Hiroshi Adachi, Kazuyuki Hiruta, Frank Thieme
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
norovirus
virus-like particle
plant-produced
vaccine
clinical trial
adults
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1021500/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1021500/full

Similar Items